Initiated H.C. Wainwright
Initiated Robert W. Baird
Initiated Evercore ISI
Sep-17-19 05:25PM Lifshitz & Miller LLP Announces Investigation of Curaleaf Holdings, Inc., Granite Construction, Inc., Karyopharm Therapeutics, Inc., ProPetro Holdings Corp., SAExploration, Inc., Sunnova Energy International, Inc., and Surface Oncology, Inc. PR Newswire -8.48%
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; SRF388 targeting interleukin 27; and SRF813 targeting CD112R. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and the Merck Sharp & Dohme Corp. to evaluate the safety and efficacy of combining Surface's SRF617, an investigational antibody therapy targeting CD39, with Merck's KEYTRUDA (pembrolizumab), the first anti-PD-1 therapy approved in the United States. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
SEC Form 4
Goater Jeff Chief Executive Officer Jan 19 Option Exercise 3.18 5,000 15,900 267,000 Jan 21 08:17 PM Goater Jeff Chief Executive Officer Jan 19 Sale 13.00 5,000 65,000 262,000 Jan 21 08:17 PM ROSS ROBERT W. Chief Medical Officer Jan 15 Sale 12.25 2,000 24,500 89,000 Jan 15 08:00 PM ROSS ROBERT W. Chief Medical Officer Jan 14 Sale 11.95 7,000 83,650 91,000 Jan 15 08:00 PM Atlas Venture Fund IX, L.P. 10% Owner Dec 17 Sale 18.10 1,700,000 30,770,000 2,945,453 Dec 21 01:32 PM GRAYZEL DAVID S. Director Dec 17 Sale 18.10 1,700,000 30,770,000 2,945,453 Dec 21 01:32 PM ROSS ROBERT W. Chief Medical Officer Dec 15 Sale 10.48 1,000 10,480 98,000 Dec 17 08:00 PM ROSS ROBERT W. Chief Medical Officer Dec 11 Sale 10.05 1,405 14,120 99,000 Dec 15 08:00 PM FEES JESSICA See Remarks Nov 25 Option Exercise 5.06 1,383 6,996 102,183 Nov 27 08:00 PM ROSS ROBERT W. Chief Medical Officer Nov 11 Sale 10.05 595 5,980 100,405 Nov 13 08:00 PM FEES JESSICA See Remarks Oct 28 Option Exercise 4.14 4,895 20,262 100,800 Oct 30 08:30 PM ROSS ROBERT W. Chief Medical Officer Oct 14 Sale 10.05 4,000 40,200 101,000 Oct 16 08:02 PM EcoR1 Capital, LLC 10% Owner Sep 01 Sale 7.14 332,780 2,376,681 4,701,081 Sep 03 04:17 PM New Enterprise Associates 14, 10% Owner May 20 Sale 3.66 420,000 1,535,562 2,892,877 May 22 04:56 PM Goater Jeff Chief Executive Officer Feb 05 Buy 3.23 5,000 16,150 262,000 Feb 07 04:05 PM
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite